CD19 and acute lymphoblastic leukemia: Tisagenlecleucel was approved for patients ≤25 years of age with second or subsequent R/R CD19+ B-ALL (U.S. and Europe) and any relapse after hematopoietic stem cell transplantation (Europe only) by the FDA in 2017 and the EMA in 2018.